Literature DB >> 25231823

[Prediction of Alzheimer's dementia].

F Jessen1, R Dodel.   

Abstract

The prediction of Alzheimer's dementia is relevant for the development and design of prevention trials but also for individual counselling of patients. There are two key characteristics which determine the level of prediction that can be achieved. Firstly, the prevalence of Alzheimer's dementia in the respective setting is important. In low prevalence settings, such as primary care populations, it is probably impossible to achieve positive predictive values above 50%. In high prevalence settings, such as memory clinics, the positive predictive value of Alzheimer's dementia can be much higher. The second major characteristic is the level of cognitive impairment of an individual. The predictive power for Alzheimer's dementia increases from the cognitively healthy status to the status of progressive mild cognitive impairment. Prediction can further be increased by the use of cerebral spinal fluid and brain imaging biomarkers of Alzheimer's disease. The combination of different biomarkers may increase prediction even further. The present article reviews studies and outlines the principles of prediction of Alzheimer's dementia.

Entities:  

Mesh:

Year:  2014        PMID: 25231823     DOI: 10.1007/s00115-014-4064-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  12 in total

1.  The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia.

Authors:  S Jungwirth; S Zehetmayer; M Hinterberger; K H Tragl; P Fischer
Journal:  Int Psychogeriatr       Date:  2012-02-03       Impact factor: 3.878

2.  Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.

Authors:  Miia Kivipelto; Tiia Ngandu; Tiina Laatikainen; Bengt Winblad; Hilkka Soininen; Jaakko Tuomilehto
Journal:  Lancet Neurol       Date:  2006-09       Impact factor: 44.182

3.  Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study.

Authors:  S M C Rasquin; J Lodder; P J Visser; R Lousberg; F R J Verhey
Journal:  Dement Geriatr Cogn Disord       Date:  2004-12-09       Impact factor: 2.959

4.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Authors:  Peder Buchhave; Lennart Minthon; Henrik Zetterberg; Asa K Wallin; Kaj Blennow; Oskar Hansson
Journal:  Arch Gen Psychiatry       Date:  2012-01

5.  Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data.

Authors:  Jesus J Gomar; Concepcion Conejero-Goldberg; Peter Davies; Terry E Goldberg
Journal:  Alzheimers Dement       Date:  2014-03-06       Impact factor: 21.566

6.  Prediction of dementia in primary care patients.

Authors:  Frank Jessen; Birgitt Wiese; Horst Bickel; Sandra Eiffländer-Gorfer; Angela Fuchs; Hanna Kaduszkiewicz; Mirjam Köhler; Tobias Luck; Edelgard Mösch; Michael Pentzek; Steffi G Riedel-Heller; Michael Wagner; Siegfried Weyerer; Wolfgang Maier; Hendrik van den Bussche
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

7.  The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment.

Authors:  Timo Grimmer; Carolin Wutz; Alexander Drzezga; Stefan Förster; Hans Förstl; Marion Ortner; Robert Perneczky; Alexander Kurz
Journal:  Curr Alzheimer Res       Date:  2013-01       Impact factor: 3.498

8.  Predicting decline in mild cognitive impairment: a prospective cognitive study.

Authors:  Sylvie Belleville; Serge Gauthier; Emilie Lepage; Marie-Jeanne Kergoat; Brigitte Gilbert
Journal:  Neuropsychology       Date:  2014-03-03       Impact factor: 3.295

9.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Authors:  Niklas Mattsson; Henrik Zetterberg; Oskar Hansson; Niels Andreasen; Lucilla Parnetti; Michael Jonsson; Sanna-Kaisa Herukka; Wiesje M van der Flier; Marinus A Blankenstein; Michael Ewers; Kenneth Rich; Elmar Kaiser; Marcel Verbeek; Magda Tsolaki; Ezra Mulugeta; Erik Rosén; Dag Aarsland; Pieter Jelle Visser; Johannes Schröder; Jan Marcusson; Mony de Leon; Harald Hampel; Philip Scheltens; Tuula Pirttilä; Anders Wallin; Maria Eriksdotter Jönhagen; Lennart Minthon; Bengt Winblad; Kaj Blennow
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

10.  A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.

Authors:  Agneta Nordberg; Stephen F Carter; Juha Rinne; Alexander Drzezga; David J Brooks; Rik Vandenberghe; Daniela Perani; Anton Forsberg; Bengt Långström; Noora Scheinin; Mira Karrasch; Kjell Någren; Timo Grimmer; Isabelle Miederer; Paul Edison; Aren Okello; Koen Van Laere; Natalie Nelissen; Mathieu Vandenbulcke; Valentina Garibotto; Ove Almkvist; Elke Kalbe; Rainer Hinz; Karl Herholz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-08       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.